• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury.
CONCLUSIONS: The pharmacologic agent with the most supporting literature is amantadine used for cognitive improvement after TBI. Other neurostimulants with positive, despite more limited, evidence include methylphenidate, modafinil, levodopa, and citalopram. Caution is warranted with other neurostimulants given higher rates of adverse effects or lack of benefit observed in clinical trials. PMID: 33435717 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - January 12, 2021 Category: Drugs & Pharmacology Authors: Kakehi S, Tompkins DM Tags: Ann Pharmacother Source Type: research

Probable Nootropic-induced Psychiatric Adverse Effects: A Series of Four Cases
Conclusion Healthcare providers in general, and specifically those in the mental health and substance abuse fields, should keep in mind that nootropic use is an under recognized and evolving problem. Nootropic use should be considered in cases where there are sudden or unexplained exacerbations of psychiatric symptoms in patients who have been stable and medication adherent. It is also important to remember that most nootropics are not detected on standard drug toxicology screening tests. We have very little clinical information on how nootropics may interact with psychotropics (or other medications) and potentially cause ...
Source: Innovations in Clinical Neuroscience - December 1, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Case Series and Literature Review Current Issue Mental Disorders Psychiatry Psychopharmacology Substance Use Disorders Ampakines Armodafinil brain enhancer Cerebrolysin Citicoline cognitive enhancer homeopathic medicine natural r Source Type: research

The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke.
CONCLUSION: Our systematic review demonstrates an evolving evidence base to suggest some benefits in agitation and aggression, mood and attentional deficits. However, there are key limitations of the studies undertaken to date involving small numbers of participants, heterogeneous outcome measures, and variable study designs. There is a need for on-going large prospective double-blind RCTs in these medications using standardised criteria and outcomes to fully understand their effectiveness in this patient group. PMID: 25850757 [PubMed - as supplied by publisher]
Source: Acta Neuropsychiatrica - April 11, 2015 Category: Psychiatry Tags: Acta Neuropsychiatr Source Type: research

Adult onset methylphenidate induced dyskinesia after stroke
Methylphenidate is a stimulant medication that is commonly used to treat attention-deficit/hyperactivity disorder (ADHD). It is also used as adjuvant therapy for improving disability after stroke. Recently, Moreau et al. reported that methylphenidate improved gait hypokinesia and freezing in patients with advanced Parkinson's disease (PD) . The most common side effects of methylphenidate are; insomnia, anorexia, weight loss, abdominal pain, headache, irritability, anxiety, tachycardia, hypertension, and motor tics. Dyskinesia as a side effect of methylphenidate is rare, and only a few cases have been reported . Most of th...
Source: Parkinsonism and Related Disorders - April 14, 2014 Category: Neurology Authors: Jeong Yeon Kim, Jong Sam Baik Tags: Letters to the Editor Source Type: research